-
1
-
2
-
3
Daclizumab a novel corticosteroid-sparing therapy for asthma?: Evaluation of: Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178:1002-8
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
4
Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension: Evaluation of: Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178(1):81-8
Veröffentlicht in Expert opinion on therapeutic targets
VolltextArtikel -
5
PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport?: Evaluation of: Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafi l and vardenafi l activate chloride transport in cystic fi brosis. Am J Respir Crit Care Med 2008;177(5):506-15
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
6
Infliximab for the therapy of chronic sarcoidosis: BAUGHMAN RP, DRENT M, KAVURU M et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. (2006) 174(7):795-802
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
7
Golimumab for severe asthma: Evaluation: Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
8
Rituximab for refractory Wegener's granulomatosis: KEOGH KA, YTTERBERG SR, FERVENZA FC et al.: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med. (2006) 173(2):180-187
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
9
Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension: KATAOKA M, NAGAYA N, SATOH T et al.: A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2005) 172(12):1575-1580
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
10
-
11
Bosentan for the treatment of idiopathic pulmonary fibrosis: Evaluation of: King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med 2008;177: 75-81
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
12
Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?: VAN DER VAART H, KOETER GH, POSTMA DS, KAUFFMAN HF, TEN HACKEN NH: First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2005) 172(4):465-469
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
13
-
14
Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation: AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040-1047
Veröffentlicht in Expert opinion on investigational drugs
VolltextArtikel -
15
-
16
Itraconazole for severe asthma with fungal sensitivity: Evaluation of: Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009;179(1):11-8
Veröffentlicht in Expert opinion on pharmacotherapy
VolltextArtikel -
17
Inhaled corticosteroids in COPD: systemic effects of a local therapy?: Evaluation of Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177(11):1207-14
Veröffentlicht in Expert opinion on pharmacotherapy
VolltextArtikel -
18
Sildenafil for the treatment of altitude-induced hypoxaemia: RICHALET J-P, GRATADOUR P, ROBACH P et al.: Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am. J. Respir. Crit. Care. Med. (2005) 171:275-281 [1]
Veröffentlicht in Expert opinion on pharmacotherapy
VolltextArtikel -
19
-
20